Hypercoagulation among Non-small Cell Lung Carcinoma Patients
| Main Authors: | Eppy, Eppy; Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, A, Harsal; Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, Z, Amin; Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, G, Nainggolan; Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital, D, Atmakusuma; Faculty of Medicine Universitas Indonesia, Cipto Mangunkusumo Hospital |
|---|---|
| Format: | application/pdf eJournal |
| Bahasa: | eng |
| Terbitan: |
Journal of the Indonesian Medical Association
, 2007
|
| Online Access: |
http://indonesia.digitaljournals.org/index.php/idnmed/article/view/484 |
Daftar Isi:
- The prevalence of thromboembolism in cancer was reported to be the highest in lung cancer. The risk of thromboembolism is higher in adenocarcinoma, in patients receiving anticancer treatment, or in the presence of metastasis. Hypercoagulation is considered the fundamental mechanism of the disorder. Some comorbidities could worsen the hypercoagulation. This study aimed to find out the hypercoagulation proportion and the distribution and association between stage, cyto/histopathology, anticancer treatment, and comorbidity and hypercoagulation rate in non–small cell lung cancer patients. Fourty two subjects registered at Dharmais and Cipto Mangunkusumo Hospital between July and October 2005 were enrolled in this study. Hypercoagulation was determined by PT, prothrombine activity, INR, aPTT, and D-dimer tests. The variables that were assessed included stage, cyto/histopathology, anticancer treatment, comorbidity, and hypercoagulation rate. Most subjects were in stage IV (76.2%); most cyto/histopathologic findings were adenocarcinoma (71.4%); 54.8% subjects had been treated with anticancer treatment; and 54.8 % subjects had comorbidity. Hypercoagulation was found in 64,3% subjects with hemostasis abnormalities including: shortened PT (7.4%), increased prothrombine activity (33.3%), decreased INR (51.9%), shortened aPTT (22.2%), and increased D-dimer (55.6%). The hypercoagulation rate was higher in group with stage IV (OR 1.27), group receiving anticancer treatment (OR 6.53), and group with comorbidity (OR 1.66). There was no tendency of hypercoagulation in group with adenocarcinoma.Keywords: non-small cell lung cancer, hypercoagulation